



Cite this: *Photochem. Photobiol. Sci.*, 2019, **18**, 259

DOI: 10.1039/c8pp90049c  
[rsc.li/pps](http://rsc.li/pps)

## Correction: Photobiomodulation: lasers vs. light emitting diodes?

Vladimir Heiskanen<sup>a</sup> and Michael R. Hamblin<sup>\*b,c,d</sup>

Correction for 'Photobiomodulation: lasers vs. light emitting diodes?' by Vladimir Heiskanen and Michael R. Hamblin, *Photochem. Photobiol. Sci.*, 2018, **17**, 1003–1017.

The Conflicts of Interest statement should be corrected to include a list of potential conflicts.

Dr Hamblin is on the following Scientific Advisory Boards: Transdermal Cap Inc, Cleveland, OH; BeWell Global Inc, Wan Chai, Hong Kong; Hologenix Inc, Santa Monica, CA; LumiThera Inc, Poulsbo, WA; Vielight, Toronto, Canada; Bright Photomedicine, Sao Paulo, Brazil; Quantum Dynamics LLC, Cambridge, MA; Global Photon Inc, Bee Cave, TX; Medical Coherence, Boston MA; NeuroThera, Newark DE; JOOVV Inc, Minneapolis-St Paul MN; Illumiheal & Petthera, Shoreline, WA; MB Lasertherapy, Houston, TX.

Dr Hamblin has been a consultant for USHIO Corp, Japan; Merck KGaA, Darmstadt, Germany; Philips Electronics Nederland B.V.; Johnson & Johnson Inc, Philadelphia, PA; AIRx Medical, Pleasanton CA; FIR Industries, Inc. Ramsey, NJ; UVLRx Therapeutics, Oldsmar, FL; Ultralux UV Inc, Lansing MI; Photothera Inc, Carlsbad, CA.

The Royal Society of Chemistry apologises for these errors and any consequent inconvenience to authors and readers.

<sup>a</sup>Oral and Maxillofacial Diseases, University of Helsinki, Finland

<sup>b</sup>Wellman Center for Photomedicine, Massachusetts General Hospital, Boston, MA 02114, USA

<sup>c</sup>Department of Dermatology, Harvard Medical School, Boston, MA 02115, USA

<sup>d</sup>Harvard-MIT Division of Health Sciences and Technology, Cambridge, MA 02139, USA. E-mail: [hamblin@helix.mgh.harvard.edu](mailto:hamblin@helix.mgh.harvard.edu)

